References
- Abernethy, D. R. (1989). The pharmacokinetic profile of amlodipine. Am. Heart J. 118, 1100-1103 https://doi.org/10.1016/0002-8703(89)90834-X
- Arrowsmith, J. E., Campbell, S. F., Cross, P. E., Stubbs, J. K., Burges, R. A., Gardiner, D. G. and Blackburn, K. J. (1986). Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents. J. Med. Chem. 29, 1696-1702 https://doi.org/10.1021/jm00159a022
- Beresford, A. P., McGibney, D., Humphrey, M. J., Macrae, P. V. and Stopher, D. A. (1988). Metabolism and kinetics of amlodipine in man. Xenobiotica. 18, 245-254 https://doi.org/10.3109/00498258809041660
- Burges, R. A., Gardiner, D. G., Gwilt, M., Higgins, A. J., Blackburn, K. J., Campbell, S. F., Cross, P. E. and Stubbs, J. K. (1987). Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: evidence for voltage modulation of vascular dihydropyridine receptors. J. Cardiovasc. Pharmacol. 9, 110-119
- Burke, D. and Henderson, D. J. (2002). Chirality: a blueprint for the future. Br. J. Anaesth. 88, 563-576 https://doi.org/10.1093/bja/88.4.563
- Dodd, M. G., Gardiner, D. G., Carter, A. J., Sutton, M. R. and Burges, R. A. (1989). The hemodynamic properties of amlodipine in anesthetised and conscious dogs: comparison with nitrendipine and influence of beta-adrenergic blockade. Cardiovasc. Drugs Ther. 3, 545-555 https://doi.org/10.1007/BF01865514
- Goldmann, S., Stoltefuss, J. and Born, L. (1992). Determination of the absolute configuration of the active amlodipine enantiomer as (-)-S: a correction. J. Med. Chem. 35, 3341-3344 https://doi.org/10.1021/jm00096a005
- Lee, B. H., Seo, H. W., Kwon, K. J., Yoo, S. E. and Shin, H. S. (1999). In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist. J. Cardiovasc. Pharmacol. 33, 375-382 https://doi.org/10.1097/00005344-199903000-00005
- Lee, B. H., Seo, H. W., Yoo, S. E., Kim, S. O., Lim, H. and Shin, H. S. (2001). Differential action of KR-31378, a novel potassium channel activator, on cardioprotective and hemodynamic effects. Drug Dev. Res. 54, 182-190 https://doi.org/10.1002/ddr.10028
- Lee, B. H., Yoo, S. E. and Shin, H. S. (1998). Hemodynamic profile of SKP-450, a new potassium-channel activator. J. Cardiovasc. Pharmacol. 31, 85-94 https://doi.org/10.1097/00005344-199801000-00013
- Lee, J. (2006). S-(-)-Amlodipine camsylate or hydrate thereof and pharmaceutical composition containing salt. KP2006-0068401 (in application)
- Meredith, P. A. and Elliott, H. L. (1992). Clinical pharmacokinetics of amlodipine. Clin. Pharmacokinet. 22, 22-31 https://doi.org/10.2165/00003088-199222010-00003
- Park, J. Y., Kim, K. A., Lee, G. S., Park, P.W., Kim, S. L., Lee, Y. S., Lee, Y. W. and Shin, E. K. (2004). Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects. Clin. Ther. 26, 715-723 https://doi.org/10.1016/S0149-2918(04)90071-9
- Park, J. Y., Kim, K. A., Park, P. W., Lee, O. J., Ryu, J. H., Lee, G. H., Ha, M. C., Kim, J. S., Kang, S. W. and Lee, K. R. (2006). Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. Clin Ther. 28, 1837-1847 https://doi.org/10.1016/j.clinthera.2006.11.008
- Rentsch, K. M. (2002). The importance of stereoselective determination of drugs in the clinical laboratory. J. Biochem. Biophys. Methods. 54, 1-9 https://doi.org/10.1016/S0165-022X(02)00124-0
- Shin, H. S., Seo, H. W., Yoo, S. E. and Lee, B. H. (1998). Cardiovascular pharmacology of SKP-450, a new potassium channel activator, and its major metabolites SKP-818 and SKP-310. Pharmacology 56, 111-124 https://doi.org/10.1159/000028188
- Spargo, P. L. (1995). Separation of the enantiomers of amlodipine via their diastereomeric tartrates. WO9525722
- Tucker, G. T. (2000). Chiral switches. Lancet. 355, 1085-1087 https://doi.org/10.1016/S0140-6736(00)02047-X
- Walker, D. K., Humphrey, M. J. and Smith, D. A. (1994). Importance of metabolic stability and hepatic distribution to the pharmacokinetic profile of amlodipine. Xenobiotica. 24, 243-250 https://doi.org/10.3109/00498259409043236
- Yamanaka, K., Suzuki, M., Munehasu, S. and Ishiko, J. (1991). Antihypertensive effects of amlodipine, a new calcium antagonist. Nippon Yakurigaku Zasshi 97, 115-126 https://doi.org/10.1254/fpj.97.2_115
- Zhang, X. P., Loke, K. E., Mital, S., Chahwala, S. and Hintze, T. H. (2002). Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine. J. Cardiovasc. Pharmacol. 39, 208-214 https://doi.org/10.1097/00005344-200202000-00007